A new study, led by Professor John Deanfield from University College London (UCL), reveals that the anti-obesity medication ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.

Halia plans to advance HT-6184 into a Phase 2 clinical trial for obesity later this year. This trial will evaluate the safety, tolerability, and efficacy of HT-6184 in combination with semaglutide for ...

Researchers found that patients with obesity had an average weight loss of 12.9% with semaglutide vs 5.6% with liraglutide ...

At least a dozen experimental weight-loss drugs designed to be taken as pills are working their way through clinical trials, ...

Semaglutide injections effectively support weight loss by regulating appetite and glucose levels, offering benefits for ...

Among patients receiving persistent medication at one year, 61% of patients prescribed semaglutide for obesity achieved at ...

Long-term weight loss for patients with obesity proved mostly successful after taking prescription-only injectable ...

Weight loss injections are essentially the opposite of pills in terms of pros and cons. They’re generally more effective and ...

Why fork over thousands of dollars a month for prescription weight loss jabs when store-bought supplements claim to have the ...

Researchers used real-world data to identify key factors for long-term weight loss for patients taking GLP-1 drugs like Ozempic and Wegovy.

Compounded semaglutide has emerged as a significant development in the management of obesity and type 2 diabetes. As a ...